(2026). An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib. Thoracic Cancer.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"An Observational Study of Afatinib 30 Mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib."
Thoracic Cancer 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"An Observational Study of Afatinib 30 Mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib."
Thoracic Cancer, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.